{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:51:53Z","timestamp":1757314313502,"version":"3.41.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Carcinoid heart disease is a frequent manifestation of carcinoid syndrome. It results from the release of a large amount of serotonin and subsequently fibrosis of right sided heart valves, that is, tricuspid and pulmonic valve. This article reviews the pathogenesis, clinical symptoms, diagnosis, treatment and prognosis of carcinoid heart disease. Recent developments in treating carcinoid heart disease have improved the poor prognosis associated with the disease.<\/jats:p>","DOI":"10.1097\/crd.0000000000000475","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T15:00:20Z","timestamp":1671030020000},"page":"193-198","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Past, Present, and The Future of Carcinoid Heart Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Juliet","family":"Meir","sequence":"first","affiliation":[{"name":"From the Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Vaslhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Michaud","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Vaslhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Vaslhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"From the Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Vaslhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors.","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.10-2-123","article-title":"Metastatic carcinoid tumors: a clinical review.","volume":"10","author":"Zuetenhorst","year":"2005","journal-title":"Oncologist"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0002-8703(52)90182-8","article-title":"Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography.","volume":"44","author":"Biorck","year":"1952","journal-title":"Am Heart J"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.21037\/jtd.2019.08.71","article-title":"Hedinger syndrome: first experience and two-year follow-up in patients with carcinoid heart disease.","volume":"11","author":"El Gabry","year":"2019","journal-title":"J Thorac Dis"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11936-013-0265-2","article-title":"Carcinoid valve disease.","volume":"15","author":"Askew","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2014.02.037","article-title":"The clinical presentation and management of carcinoid heart disease.","volume":"173","author":"Dobson","year":"2014","journal-title":"Int J Cardiol"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","article-title":"Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.","volume":"10","author":"Mawe","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease.","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.amjcard.2004.01.075","article-title":"Carcinoid heart disease associated with primary ovarian carcinoid tumor.","volume":"93","author":"Chaowalit","year":"2004","journal-title":"Am J Cardiol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"R14-20250619","first-page":"827","article-title":"Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects.","volume":"10","author":"Rajamannan","year":"2001","journal-title":"J Heart Valve Dis"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment--\u201csomething in the way it moves.\u201d","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcct.2020.08.009","article-title":"Features of carcinoid heart disease identified by cardiac computed tomography.","volume":"15","author":"Davar","year":"2021","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2007.08.045","article-title":"Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century.","volume":"101","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","article-title":"Carcinoid heart disease: presentation, diagnosis, and management.","volume":"90","author":"Fox","year":"2004","journal-title":"Heart"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000507847","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management.","volume":"146","author":"Jin","year":"2021","journal-title":"Cardiology"},{"key":"R21-20250619","first-page":"9142598","article-title":"Carcinoid syndrome-induced ventricular tachycardia.","volume":"2016","author":"Rupp","year":"2016","journal-title":"Case Rep Cardiol"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement.","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours.","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","article-title":"Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).","volume":"26","author":"Kanakis","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2008.18.7047","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.","volume":"27","author":"Korse","year":"2009","journal-title":"J Clin Oncol"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease.","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors.","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000225952","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation.","volume":"90","author":"Arnold","year":"2009","journal-title":"Neuroendocrinology"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0735-1097(02)02109-5","article-title":"Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients.","volume":"40","author":"Pandya","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ehf2.12328","article-title":"Exercise cardiac magnetic resonance imaging with pulmonary artery catheter monitoring in carcinoid heart disease: a shift towards early intervention?","volume":"5","author":"Timmermans","year":"2018","journal-title":"ESC Heart Fail"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/AC.67.2.2154218","article-title":"Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance.","volume":"67","author":"Moerman","year":"2012","journal-title":"Acta Cardiol"},{"key":"R60-20250619","doi-asserted-by":"crossref","first-page":"e001060","DOI":"10.1136\/openhrt-2019-001060","article-title":"Multimodality imaging in carcinoid heart disease.","volume":"6","author":"Agha","year":"2019","journal-title":"Open Heart"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the society for cardiovascular magnetic resonance.","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"suppl 4","key":"R35-20250619","first-page":"iv1","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.","volume":"54","author":"Ramage","year":"2005","journal-title":"Gut"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI.","volume":"3","author":"Bhattacharyya","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcct.2010.08.009","article-title":"Computed tomography of cardiac and pericardiac masses.","volume":"5","author":"Rajiah","year":"2011","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11886-019-1196-7","article-title":"The assessment of cardiac masses by cardiac CT and CMR including pre-op 3D reconstruction and planning.","volume":"21","author":"Liddy","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"W294","DOI":"10.2214\/AJR.07.2936","article-title":"Cardiac valve disease: spectrum of findings on cardiac 64-MDCT.","volume":"190","author":"Ryan","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"L14","DOI":"10.1007\/s00330-002-1806-3","article-title":"MRI and CT revealing carcinoid heart disease.","volume":"13","author":"Mollet","year":"2003","journal-title":"Eur Radiol"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.acvd.2010.03.011","article-title":"Cardiac computed tomography in right-sided carcinoid heart disease.","volume":"104","author":"Fares","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/icvts\/ivu146","article-title":"Prognosis of patients with carcinoid heart disease after valvular surgery.","volume":"19","author":"Manoly","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0735-1097(98)00354-4","article-title":"Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.","volume":"32","author":"Denney","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","article-title":"Therapeutic options for gastrointestinal carcinoids.","volume":"4","author":"Modlin","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/1535-7163.MCT-09-0820","article-title":"A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2\/neu-expressing malignancies.","volume":"8","author":"Bekaii-Saab","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","article-title":"Early and late outcomes of surgical treatment in carcinoid heart disease.","volume":"66","author":"Connolly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0735-1097(94)00374-Y","article-title":"Outcome of cardiac surgery for carcinoid heart disease.","volume":"25","author":"Connolly","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R50-20250619","doi-asserted-by":"crossref","first-page":"398","DOI":"10.21470\/1678-9741-2017-0224","article-title":"Quadruple valve replacement for carcinoid heart disease.","volume":"33","author":"Mujtaba","year":"2018","journal-title":"Braz J Cardiovasc Surg"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.10.87","article-title":"Surgery for carcinoid heart disease: current outcomes, concerns and controversies.","volume":"6","author":"Raja","year":"2010","journal-title":"Future Cardiol"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtcvs.2018.09.025","article-title":"Improving outcome of valve replacement for carcinoid heart disease.","volume":"158","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jacc.2015.05.086","article-title":"Carcinoid heart disease: the challenge of the unknown known.","volume":"66","author":"Warner","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.beem.2015.09.005","article-title":"Carcinoid heart disease: diagnosis and management.","volume":"30","author":"Luis","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/0002-8703(91)90045-J","article-title":"Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease.","volume":"121","author":"Ridker","year":"1991","journal-title":"Am Heart J"},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ejcts\/ezu201","article-title":"Misconceptions","volume":"47","author":"Pislaru","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2014.468","article-title":"Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.","volume":"111","author":"Dobson","year":"2014","journal-title":"Br J Cancer"},{"key":"R58-20250619","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease.","volume":"348","author":"Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"R59-20250619","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","article-title":"Risk factors for the development and progression of carcinoid heart disease.","volume":"107","author":"Bhattacharyya","year":"2011","journal-title":"Am J Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:00:47Z","timestamp":1750348847000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000475","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}